Navigation Links
Arsenal Capital Partners übernimmt führendes Unternehmen für modellbasierte Arzneimittelentwicklung Certara
Date:12/20/2013

NEW YORK, 20. Dezember 2013 /PRNewswire/ -- Arsenal Capital Partners, ein führendes Private-Equity-Unternehmen mit Sitz in New York, das in mittelständische Gesundheits- und Spezialindustrieunternehmen investiert, verkündete heute die Übernahme von Certara, dem führenden Anbieter modellbasierter Arzneimittelentwicklung, Datenanalysesoftware und Beratungsdienstleistungen für den Markt biopharmazeutischer Forschung und Entwicklung.

Certara bietet hochspezialisierte und integrierte Lösungen an, die auf rechnergestützten Modellen basieren und durch führende wissenschaftliche Beratungsdienstleistungen unterstützt werden. Sie werden für die Entdeckungsphase, die vorklinische sowie klinische Phase der Arzneimittelentwicklung angeboten. Dank der Lösungen von Certara reduzieren sich für Klienten Zeit und Kosten für die Einführung von Arzneimitteln auf den Markt maßgeblich, indem datengesteuerte Entscheidungen ermöglicht werden, die zu einem präziseren Studienaufbau mit geringerem Risiko zum Scheitern und verbesserter Sicherheit der Studiensubjekte führen – ein Vorteil der stark regulierten und zunehmend teureren Forschungs- und Entwicklungsumgebung.

Stephen McLean, ein Partner bei Arsenal und Co-Head der Healthcare Group des Unternehmens erklärte: „Wir sind über unsere Investition in dieses spannende Unternehmen, das einen solch wichtigen Beitrag zur Verbesserung der Produktivität des Arzneimittelentwicklungsprozesses leistet, hocherfreut. Die durchschnittlichen Kosten für die Forschung und Entwicklung eines neuen Arzneimittels liegen heute über 1,5 Mrd. US-Dollar und die Dauer beträgt 10 bis 15 Jahre. Das steht in einem klaren Widerspruch zur Notwendigkeit, die Kosten der globalen Gesundheitsfürsorge zu senken, und Certara wird einen we
'/>"/>

SOURCE Arsenal Capital Partners
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arsenal Capital Partners verwerft Certara, leider in geneesmiddelontwikkeling op basis van modellen
2. Arsenal Capital Partners Acquires Leading Model-Based Drug Development Company Certara
3. Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
4. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
5. TVM Capital Group Announces Two-pronged Global Investment Strategy with Renewed MENA Focus
6. Foundation Venture Capital Group Portfolio Company Identifies FRY Gene As Breast Cancer Susceptibility Suppressor
7. S&P Capital IQ to Share Its Views on the Biotech Bull Market During the Next "ETF Analyst Hour"
8. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
9. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
10. GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
11. Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 26, 2014 Genedata, a leading ... and life science research, today announced the ... be held in Asia, Europe, and North America ... companies and leading research organizations will gather for ... case studies, and upcoming challenges in all areas ...
(Date:8/26/2014)... CITY, Calif. , Aug. 26, 2014 /PRNewswire/ ... development and commercialization of oncology diagnostic products, has ... as a 2015 Technology Pioneer . As ... is one of 24 companies across a wide ... prestigious accolade. Guardant360 ® , ...
(Date:8/26/2014)... Cary, NC (PRWEB) August 26, 2014 ... built-in GMP processes, implemented a new pricing structure with ... better comply with cGMP and 21 CFR Part 11 ... Good Manufacturing Practices any way we can” said Rick ... the number of available users allowed customers to have ...
(Date:8/26/2014)... 26, 2014 Historically, drug development ... list continues to grow – high attrition rate, ... and development, high regulatory hurdles and increasing ... become clear that the traditional business model of ... are now seeking to find better ways to ...
Breaking Biology Technology:Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2Transitioning from Bench into Clinical Phase, new webinar hosted by Xtalks 2
... Verenium Corporation (Nasdaq: VRNM ), a ... today announced that it has entered into an agreement ... United States ("Ex-Im Bank") for two 18-month, secured revolving ... These new credit facilities will allow the Company ...
... 2011 PharmaVentures today announced the launch of ... Essential Deal Trends: Oncology 2011 . This new series ... and commercialising new drugs. The first report in the series ... active deal making therapeutic area in the pharmaceutical and biotechnology ...
... cell carcinomas are amongst the most frequent cancers in ... like many other human cancers, contain particular cancer cells, ... potential that sustain tumor growth. Little is known about ... High level of VEGF expression in skin cancer ...
Cached Biology Technology:Verenium Announces Up to $16 Million in New Secured Financings 2Verenium Announces Up to $16 Million in New Secured Financings 3Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends 2Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends 3New role for Vascular Endothelial Growth Factor in regulating skin cancer stem cells 2
(Date:8/25/2014)... Scientists have known that toxic effects of substances ... both natural and human-made materials, can pass from ... shows that females with ancestral exposure to EDC ... According to a new study by researchers from ... State University, male and female rats are affected ...
(Date:8/25/2014)... 133 active fires in the North Slave Region of the ... 24 hours. Fire danger is moderate to high. Smoke ... Lake Complex of fires are in an area approximately 80 ... north of Fort Providence. Four crews will be working ... week. Mop-up continues many areas of complex,s fire perimeter. The ...
(Date:8/25/2014)... a lightning strike on August 12, 2014. Currently the ... There are close to 2,000 personnel working on this ... and a number of large ones. Most of the ... 100 acres. An inversion layer settled over the fire ... keeping fire activity moderate. As the inversion lifted in the ...
Breaking Biology News(10 mins):Exposure to toxins makes great granddaughters more susceptible to stress 2Happy Camper and July Fire Complexes in California 2
... Va.Though many policymakers have argued that environmental regulations ... a new study by George Mason University researcher ... production processes can not only offset the costs ... The study, which looked at more than ...
... branch of Munich (Germany) based Genomatix Software GmbH, announced ... to provide Genomatix software and data content to Pfizer ... Pfizer are designed to show how genes are regulated ... the software and data content to help understand the ...
... International,Inc. (OTC Bulletin Board: BKYI), a leader in ... issued the following,open letter to its shareholders discussing ... performance., Highlights:, -- Revenue growth from ... in our installed base of law enforcement customers, ...
Cached Biology News:Corporations can profit from being environmentally friendly 2BIO-key(R) Issues Open Letter to Shareholders 2BIO-key(R) Issues Open Letter to Shareholders 3BIO-key(R) Issues Open Letter to Shareholders 4BIO-key(R) Issues Open Letter to Shareholders 5
...
...
... Formulation: 50mM Tris-HCl, pH 7.5, ... PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol ... (Protein Phosphatase 2A1) partially purified ... precipitation, QSepharose,amino-hexyl agarose, Superdex 200, ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Biology Products: